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Abstract 
 
 Amyotrophic Lateral Sclerosis (ALS) is a terminal neurodegenerative disease 
with symptoms including limb-onset muscle wasting, difficulties swallowing and 
breathing, leading to death. Sporadic ALS occurs in 90% of patients, while 10% of cases 
are familial (FALS). Twenty percent of FALS cases are a result of mutation in the 
copper-zinc superoxide dismutase (SOD1) gene, leading to the activation of the 
mitochondrial apoptosis pathway. Meanwhile, a prominent cause of sporadic ALS is 
exposure to neurotoxins, such as β-methylamino-L-alanine (BMAA). BMAA has been 
suggested to induce selective motor neuron death, which is observed in ALS patients. 
While research has been done to how BMAA may impacts organisms on the cellular 
level, not much has been performed on the genetic or epigenetic level. This research 
investigates how BMAA and mutations in the SOD1 gene affect the regulation of well-
known neurological genes. Within the year, zebrafish from four different genotypes were 
subjected to three different BMAA concentrations, and spinal samples from these fish 
were collected. RNA was extracted from these and cDNA was produced from the 
resulting RNA. RNA concentrations varied significantly in concentration and purity, 
while cDNA concentrations were more pure and higher in concentration. The spinal 
samples also displayed that fish exposed to 2.5 µg/L of BMAA had the lowest levels of 
actin transcripts, reflected in previous work that these fish would have the shortest motor 
neuron axons. These samples can now be used to perform transcriptome analysis to detect 
the regulation of neurological genes depending on BMAA concentration and SOD1 
mutation. 
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Introduction 
Amyotrophic Lateral Sclerosis:    
 ALS is the fourth most prevalent neurodegenerative disease, following 
Alzheimer’s, Pick’s, and Parkinson’s disease.1  Symptoms of ALS typically (70% of 
cases) start with limb-onset muscle wasting, and lead to difficulties in swallowing, 
respiratory weakness, unclear speech, depression, and eventually death.2  Research 
looking into the association with ALS and depression focuses on the prevalence of 
depression in ALS patients more often than the biological cause of depression in said 
patients3. While one-fifth of patients live up to five to ten years after symptoms begin, 
half of all patients diagnosed with ALS die within 30 months of symptom onset.2 There 
are no current cures for the disease, although there is one treatment; Riluzole. However, it 
only prolongs life for patients for a few months.4 Only between 5-10% of ALS are 
familial (FALS)5, indicating that between 90 and 95% of cases are sporadic (SALS). Of 
the FALS cases, 20% of them involve mutations in the copper-zinc superoxide dismutase 
gene (SOD1).6  
SOD1 is an enzyme found in the inner mitochondrial space and the nucleus of 
cells. It is a dimer made of two identical constitutively expressed polypeptides, bound by 
hydrophobic interactions. Each polypeptide is 153 amino acids long, and dimerization is 
stabilized and catalyzed by a zinc and copper ion. Its function is to convert superoxide 
into hydrogen peroxide.7,8 SOD1 mutations, have generally been shown to induce a toxic-
gain of function, rather than a loss of function.9 This toxic gain of function is caused by 
the aggregation of mutant SOD1 protein, and binding to B-cell lymphoma (Bcl) proteins 
on the outer membrane of mitochondria.10  
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Use of zebrafish as an ALS Model: 
The zebrafish is a useful model for studying ALS because it develops quickly, 
produces numerous offspring multiple times a day, and is more cost effective than other 
models such as a mouse or rat. More importantly, the physiology of the zebrafish 
neuromuscular system is similar to humans. This neuromuscular system develops rapidly, 
and is well characterized.12,13,14,15 . Also, since the zebrafish breeds by laying eggs in 
shallow water, its embryos are externally developed, and absorb any toxins placed into 
their environment through their derma.16.  We use several transgenic zebrafish models in 
our experiment. The models are non-transgenic SOD1 zebrafish littermates (nTG-SOD1-
wt), transgenic wildtype SOD1 zebrafish (SOD1-wt), littermates of mutant SOD1 
zebrafish (nTG-SOD1-G93R), and transgenic mutant SOD1 zebrafish (SOD1-G93R). 
Models labeled as transgenic overexpress the SOD1 allele they possess. 
   
  β – Methyamino-L-alanine: 
β – Methyamino-L-alanine (BMAA) is a non-­‐proteogenic amino acid discovered 
in high concentrations (627 µg BMAA/g brain tissue) in the brains of the Chamorro 
people, native to Guam. This is an approximately fifteen times higher concentration than 
that found in brains of people serving as neurological controls (41 µg BMAA/g brain 
tissue). This is significant because the Chamorro people had a 100x fold higher rate of 
developing ALS than the average population.10 The source of the BMAA for the 
Chamorro is cycad seeds. The cycad plants have a symbiotic relationship with 
cyanobacteria, which reside in the coralloid roots. The BMAA resulting from the 
cyanobacteria accumulates into the seeds.17  The Chamorro people would not only grind 
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cycad seeds into flour, but would also consume animals which eat cycad seeds mainly 
flying foxes. Thus, these people can acquire the amino acid through multiple sources of 
bioaccumulation.18  
BMAA does not only exist in these plants; it has been found in many fresh and 
salt water sources, including lakes in the United Kingdom 19and New Hampshire20, and 
the Baltic Sea21. People exposed multiple times to cyanobacterial harmful Algal Blooms 
(HABs) have between a 10 to 25 times chance of developing ALS than those not near 
these events.22 Also, while BMAA is primarily noted in HABs globally, 10 it is also 
produced by other organism including diatoms23 and dinoflagellates 24.  Fish and shellfish 
predate on these organism, providing another avenue for people to be exposed to BMAA 
through bioaccumulation10.   
There are multiple mechanisms proposed as to how BMAA affects motor 
neurons, depending if the amino acid is free floating or incorporated into proteins. When 
outside of the cell, free-floating BMAA acts as an agonist for glutamate receptors such as 
NMDA and AMPA/kainaite.  When introduced to mixed spinal cord culture at 30 µM, 
BMAA was shown to induce selective motor neuron death, demonstrating it as a potential 
mechanism for ALS development10. There are also suggestions that it can be incorporated 
into proteins, which can cause proteins to become misfolded25, and these proteins act as 
BMAA reservoirs26. Since BMAA is a fairly well known neurotoxin that is prevalent 
worldwide, and has evidence of causing symptoms of ALS, BMAA is the contending 
neurotoxin used in this research.  
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Experimental Design: 
In a previous experiment in the Sher Lab, performed by Samantha Powers 
[personal communication], zebrafish with and without the G93R SOD1 mutation were 
exposed to different concentrations of BMAA. Then the axons of the motor neurons 
located in the lumbar spines of each fish were measured. Fish without the mutation were 
observed to have shorter motor neuron axons as the concentration of BMAA exposure 
increased. Fish with the mutation and exposed to the BMAA had the shortest axons at 2.5 
µg/L BMAA concentration, but demonstrated longer axons at higher and lower BMAA 
concentrations, indicating a recovery mechanism existed to compensate for the short 
axons. This lead into curiosity about how genes were expressed when the fish had the 
mutation, and when they were exposed to different BMAA concentrations at the start of 
development. 
In past parts of this current experiment, performed by Samamtha Powers, the 
seventy-two zebrafish were distributed evenly into the four genotypes of zebrafish, and 
were exposed to three different concentrations of BMAA. After six months of living in 
non-toxic water, their lumbar spinal cords were extracted, frozen in liquid nitrogen, and 
stored at -80°C.27 Half of each sample group (3 fish per genotype per dose) were sent for 
proteomic analysis to be performed by Dr. Randall Moon, University of Washington. 28 
The remaining spines, in this current research, went through RNA extraction, cDNA 
production, and subsequent RNA expression analysis. While this current research was 
supposed to continue with microarray analysis of the spinal samples with in this research, 
time restraints prevented this from occurring. 
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Hypothesis: 
 It is known that BMAA has detrimental effects on the phenotype of motor 
neurons, from selective motor neuron death in cell culture to decreased axon length in 
motor neurons. From previous research, phenotypic change was observed in the length of 
motor neuron axons, indicating possible changes in the transcriptome and/or the 
proteasome. Through the microarray analysis, we wanted to observe the genetic 
regulation patterns exhibited in zebrafish when exposed to different concentrations in 
BMAA and when they had the SOD1-G93R mutation. Specifically, the genes involved in 
neurodevelopment would decrease when exposed to BMAA, and increase in fish with the 
G93R mutation when exposed to 5.0 µg/L BMAA.  
11 
 
Materials and Methods 
Spine extraction: Seventy-two zebrafish of four different genotypes (nTG-SOD1-wt, 
SOD1-wt, nTG-SOD1-G93R, and SOD-G93R) were exposed to three different doses of 
BMAA (0.0, 2.5, and 5.0 ug/L). The fish developed for 188 days, and were euthanized 
with Tricane-S (300mg/L) (Western Chemical INC, Ferndale, WA). Each fish was 
dissected, and the lumbar region was isolated. Spinal cords were pulled from exposed 
column. Individual spines were frozen in liquid nitrogen, and stored at -80°C.27 Half of 
the samples were sent for proteomics, while the others were saved for RNA extraction.28 
 
RNA extraction: RNA was individually extracted from 35 zebrafish lumbar spinal cords 
using a phenol-chloroform protocol. The frozen spines were homogenized using a frozen 
pestle, and TRIzol (800 µL) and 1mg/mL glycogen (200 µL) were added to each sample. 
Samples incubated in Phase Lock Gel Tubes (5 Prime, Gaithersburg, MD). Chloroform 
was added. Samples were centrifuged at 12000xg for twenty minutes at room 
temperature. The resulting pellets were washed twice, with isopropanol and 75% ethanol, 
and centrifuged after each wash. Pellets were left to dry, and the RNA were suspended in 
15 µL of nuclease-free water. RNA samples were analyzed using a NanoDrop 
spectrophotometer (NanoDrop 2000; Thermo Scientific; Rochester, NY). 
  
cDNA production: cDNA was produced in 20 µL reactions using the Applied 
Biosystems cDNA Reverse Transcription kit (Applied Biosystems; Carlsbad, CA). 
Primers used were a 1:1 ratio of Random primers, which came with the kit, and Oligo-DT 
nucleotides (Thermo Scientific, Waltham, MA). The protocol that utilizes the RNase 
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inhibitor was followed in the procedure.  The amount of RNA added per reaction was 
dependent on the yield of RNA for any given sample; samples with yields below 1000ng 
either contained 250 ng (samples 11 and 42) or 500 ng (samples 16, 22, 28, and 35) of 
RNA, while samples that had yields above 1000 ng contained 1000ng of RNA, in the 
reactions. cDNA production occurred in the PCR cycler under the following conditions: 
25°C for 10 minutes, 37°C for 120 minutes, and 85°C for 5 minutes. cDNA samples were 
analyzed using a NanoDrop spectrophotometer (NanoDrop 2000; Thermo Scientific; 
Rochester, NY). 
 
Primer quality control: The zebrafish primers were tested for quality on AB wildtype 
cDNA (Table 1). Primers were designed to target mRNA transcripts of both muscle and 
nervous tissue specific genes observed in the proteomic studies (Integrated DNA 
technologies, headquarters). 20 µL reactions were run using the protocol with the Taq 
PCR Master Mix Kit (QIAGEN Inc; Valencia, CA).  PCR ran under the following 
conditions for 39 cycles: 94°C for denaturing, 55°C for annealing, and 72°C for 
extension.  PCR samples were then run in a 2% agarose gel for evaluation of target 
amplification. 
 
qPCR: 50 ng of each cDNA were tested in duplicate to SsoAdvanced Universal SYBR 
Green Supermix (BioRad Laboratories; Hercules, CA) with actb1 zebrafish primers. 
qPCR ran under the following conditions for 39 cycles: 95°C for denaturing, and 60°C 
for annealing and extension. Samples were analyzed with CFX Manager™ Software 
(BioRad Laboratories; Hercules, CA). 
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Results 
RNA:  
To analyze the transcriptome of the zebrafish samples, RNA must first be 
collected specifically mRNA. RNA extractions were performed on the individual spines 
of the zebrafish, then analyzed the RNA samples concentrations and purity using 
spectrophotometry. Before figuring out the optimal procedure, we tested co-precipitants 
glycogen and linear acrylamide. RNA samples extracted with glycogen were ten times 
higher than those extracted with linear acrylamide. The concentration of RNA samples 
ranged from 26.3 to 725.2 ng/µL. The average concentration of RNA is 334.1 ng/µL 
(Figure 1A). Purity was measured using the A260/A280 ratio. None of the RNA samples 
have the optimal ratio of 2.0. Samples between 276 and 426 ng/µL have the highest 
A260/A280 ratios. The average purity of the RNA samples 1.62 (Figure 2A).  
 
cDNA:  
To ensure that the spinal samples would last, cDNA was produced from RNA 
through reverse transcription. DNA is a more stable molecule than RNA, so conversion 
of RNA to cDNA wound ensure that the samples would be viable when we could analyze 
them. After reverse transcription, the samples were analyzed using spectrophotometry.  
The average concentration of the cDNA samples was 2758 ng/µL. There were fewer 
cDNA samples with significantly lower yields than their counterparts, as there were 
fewer cDNA samples with significantly lower yields than their counterparts, as there was 
only one sample that was below 1500 ng/µL (54) and five samples that were above 4000 
ng/µL (53, 59, 65, 66, and 72) (Figure 1B). The A260/A280 of the cDNA samples, 
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measuring purity, are approximately 1.8 for samples between 1928 and 3200 ng/µL. The 
A260/A280 of these samples range from 1.67 to 1.82, with an average of 1.77 (Figure 2B).  
 
qPCR:  
 Before samples could go through transcriptome analysis, they must first be tested 
to make sure they are compatible with the SYBR master mix that will be used in said 
analysis. This was done by testing 50 ng of cDNA from each of all thirty-five samples 
with the same primer pair, actb1, and checked for consistent amplification. However, 
variation of the levels of actb1, or actin, transcripts were observed between samples. The 
average relative fluorescent unit (RFU) measurement was 2025 RFU. Samples with the 
G93R mutation had higher RFU measurements than their wildtype counterparts (Figure 
3A). Samples exposed to 2.5 µg/L of BMAA had lower RFU measurements than other 
samples (Figure 3B). 
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Discussion  
Overall, the results illustrated several important points about the protocols 
involved collecting samples for transcriptome analysis. Even when RNA samples were 
extracted with glycogen as the co-precipitant, the concentration of samples varied 
significantly, with less than optimal purity. These samples, when converted to cDNA, 
increased in yield and purity. When samples were tested for compatibility with the SYBR 
master mix, it was found that there was variation in actb1 levels between different 
samples. 
 Several modifications had to be made to the original RNA extraction procedure 
to increase the RNA yield as well as the purity of each RNA samples. The modification 
that increased the yield of RNA was changing the co-precipitant from linear acrylamide 
to glycogen. The changes made to protocol to make the samples purer were doubling the 
time samples were centrifuged, and increasing the temperature of centrifuging samples 
from  4°C to room temperature.  
. When testing RNA extraction methods using linear acrylamide, it was noticed 
that the RNA yields were averaging less than 50 ng/µL, so less than half of the minimum 
yield required to use in future experiments. We looked up some similar extraction 
procedures that successfully used glycogen instead of linear acrylamide as the co-
precipitant.29 From this, it was hypothesized that using glycogen as a co-precipitant 
would increase the RNA yield more than linear acrylamide. When RNA from wildtype 
AB zebrafish was extracted with both 250x linear acrylamide, and 1 mg/ mL glycogen, 
the samples extracted with glycogen exhibited higher yields. However, a possible reason 
why there might be a higher yield with glycogen than with linear acrylamide is because 
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the glycogen is added in with the TRIzol reagent before the chloroform step. This is the 
opposite of using linear acrylamide, as linear acrylamide is added after the chloroform in 
procedures that use that co-precipitant. By providing the glycogen more time to contact 
the RNA, it increased the odds of the glycogen pelleting the RNA.  
Next, it was thought that the purity of RNA samples would increase if the 
centrifuging stages in the extraction procedure were performed for double the time at 
25°C than the time suggested at 4°C. This was from consultation with Dr. Roger Sher 
[personal communication], which suggested that the salts from the TRIzol were 
precipitating into the RNA pellet when centrifuging the samples at 4°C. At room 
temperature, it was thought that these salts would not precipitate, thus increasing the 
purity of the RNA samples. This was in an attempt to prevent the salts from the TRIzol 
reagent from precipitating into the pellet, which had been previously seen to contaminate 
the RNA samples. While samples were still not found to be at the optimal purity, they 
were sufficiently purified for the RNA to be produced into cDNA for the purposes of 
expression analysis. 
  With the thirty-five RNA samples extracted, samples varied in overall yield.  This 
is contradictory to how the procedure was predicted to work, as a similar amount of RNA 
should come from similar sample sizes. The main source of error from the extraction 
procedure is most likely human error. This is due to multiple people with different levels 
of experience performing the procedure involved in the collection of RNA samples 
(Figure 1A).  
  There is a noticeable trend that samples with relatively low or high RNA have 
lower A260/A280 ratios than samples with more average concentrations (Figure 2A). While 
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low A260/A230 ratios were also observed, they were expected to be low for two reasons; 
glycogen was being used as the co-precipitant, and the main component of TRIzol is 
phenol. Residual phenol and glycogen are both known to lower the purity of nucleic acid 
samples, especially lowering A260/A230 ratios.30 Due to the very low A260/A230 ratios, and 
the relatively normal A260/A280 ratios, the A260/A280 ratio was considered the more 
accurate measurement of purity. There was consideration to precipitate RNA samples 
with poorer purity and rewash samples, but this additional procedure would decrease the 
yield enough that it would be insufficient for producing cDNA from.  
 The variation of RNA concentrations between the samples was a concern for the 
next step of the procedure, cDNA production. According to the protocol that came with 
the Applied Biosystems cDNA Reverse Transcription kit (Applied Biosystems; Carlsbad, 
CA), 1 µg of RNA was required to produce cDNA. For samples with low yields, 250 ng 
(11 and 42) or 500 ng (16, 22, 28, and 35) of RNA were used (Figure 1A). However, the 
resulting cDNA concentrations from these samples were sufficient for future analysis, 
even with smaller yields than other samples. All of the cDNA samples that were of a high 
concentration (greater than 3000 ng/µL) came from samples in which 1 µg of the 
sample’s RNA was added to the reaction mixture (10, 17,18, 23, 34, 40, 48, 53, 66, 67, 
and 72) (Figure 1B). These results show that a substantial amount of cDNA can be 
produced with a quarter of the RNA stated the protocol, but not necessarily an optimal 
amount. This is good to know for producing cDNA samples from very small pieces of 
tissue in the future. Overall, enough cDNA was produced to perform qPCR analysis on 
all of the sample. 
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 The purity of the cDNA samples was more optimal than the purity of the RNA 
samples. Unlike the RNA, the optimal A260/A280 ratio for cDNA is 1.8. Most of the cDNA 
samples have an approximate ratio of 1.8. Samples with cDNA concentrations higher 
than 3500 ng/µL are less pure, with A260/A280 ratios between 1.6 and 1.8 (Figure 2B). 
These cDNA samples are more pure than the RNA counterparts because it is suspected 
that there is less of the residual phenol in the samples. Not all of the RNA is necessary for 
most of the cDNA samples, so when the small amount of RNA is transferred to the 
reaction mixture, only some of the contaminants come with it. The small amount of 
contaminant dilutes into the 20 µL reaction mixture, and thus has less of an effect on the 
purity of the resulting cDNA sample.  
 Once all the samples were collected, it was hypothesized that the gene for actin 
could be used as a housekeeping gene for qPCR quality control. This idea stems from the 
fact that actin filaments comprise of globular actin, and these filaments are part of the 
cytoskeletons on all cell types, not just neurons. While the research did suggest that 
glycogen increased the RNA yield of samples, and purity did increase when the samples 
were centrifuged at 25°C, the levels of actin transcripts varied among samples (lowest for 
samples exposed to 2.5 µg/L BMAA.) Since this is a constitutive gene, it is expected that 
all samples should have similar relative fluorescent unit (RFU) measurements, since the 
same amount of cDNA was added into each reaction. As can be seen in the results, the 
measurements vary greatly. The measurements ranged from 75 to 3655 RFU. To observe 
whether these difference could be due to one of the experimental variables, the samples 
were color coded by genotype and BMAA exposure. There were significant differences 
between the RFUs of genotype groups, displaying greater RFU averages for transgenic 
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samples than non-transgenic samples, and samples with the G93R mutation have higher 
RFU’s than those without the mutation (Figure 3A). More analysis will have to go into 
how a constitutive gene is influenced by the amount of wild type SOD1-wt transcript and 
the G93R mutation, since these results are contradictory to what was expected. There is 
also a significant decrease of actin transcript when samples were exposed to 2.5 ug/L of 
BMAA as opposed to 0.0 ug/L and 5.0 ug/L (Figure 3B). This result is understandable, 
because previous studies in this lab have shown that the length of motor neuron axons 
decrease the most when zebrafish are exposed to a dose of 2.5 µg/L of BMAA. Actin is a 
prominent cytoskeletal protein found in actin filaments, especially in the axon, so it 
makes sense that there would be less actin transcripts in the neurons of fish exposed to 
this dosage of BMAA. 
 For future directions, there are multiple methods of studying the cDNA samples 
that we have collected. First, if possible, there should be an alternative housekeeping 
gene found to be used as a control. This way, we can observe the levels of non-
constitutive genes in comparison. While qPCR analysis was attempted with gapdh 
primers before actb1 primers were used, it was observed that the reverse primers showed 
amplification in a negative control without cDNA added. The most likely possibility of 
this observation is contamination. New primers can be designed and ordered for gapdh, 
and tested again to observe their levels in these samples. After a second useful control 
primer is found, the next step will be to test each cDNA sample with the ten primers 
mentioned in table 1. This way, we can observe basic upregulation and downregulation 
patterns of target neurological and muscle genes. These results would help scientists look 
at genetic regulation when it comes to exposure of BMAA, the G93R mutation, the 
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overexpression of the wildtype and SOD1 genes, and a combination of these factors. 
Also, we can perform microarray analysis using twelve 96 well plates from Bar Harbor 
Biotechnology containing 94 genes involved with neurotoxicity and neurodegeneration 
(and two control genes). These plates have a primer pair for distinct neurological gene in 
each well. Each plate would be used for a sample type with a genotype and an exposure 
of BMAA. For example, one plate would have cDNA from a sample(s) from non-
transgenic SOD-wt littermates exposed to 5.0 µg/L of BMAA during early development. 
This way, we can get a comprehensive look at genetic regulation of neurological genes 
depending on these conditions.  
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Conclusion 
 This research provides several conclusions that are useful for future research. 
From modifying the procedure, it is demonstrated that not only using glycogen as a co-
precipitant for extraction increases the RNA yield of a sample, but also that centrifuging 
the samples at 25°C for double the recommended time increases the purity of the RNA 
samples. These observations will be important for extracting RNA from nervous tissue in 
the future. The data also verifies the short axons measured in Samantha Power’s work; a 
correlation can be made between the fewer actin transcripts in the cell, and the shorter 
length of the axons. This means that actb1 is not a good gene to analyze if looking for a 
good housekeeping gene in the near future. It is also an indicator that the samples used in 
this experiment are consistent with zebrafish with the same genotypes used in previous 
experiments. Overall, the samples collected through this research are pure enough, and 
are at a high enough concentration, that they can be used for future transcriptome 
analysis, using microarrays to perform said analysis. The transcriptome analysis can then 
be compared with the performed proteomics. This information will then contribute 
toward the summation information toward how neurotoxins in the environment can 
influence the development of ALS, and thus lead to possible treatments for the disease. 
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Figure 1. The concentration (ng/µL) for A) RNA samples and B) cDNA products, varies 
from sample to sample.  
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Figure 2. A260/A280 ratios are dependent on the nucleic acid concentration. A) A260/A280  
ratio dependent on RNA concentration (ng/µL). B) A260/A280 ratio dependent on cDNA 
concentration (ng/µL).  	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Figure 3. RFU measurements of actb1 transcripts are different depending on genotype 
and BMAA concentration zebrafish were exposed to. A) RFU depending on genotype. 
B) RFU depending on BMAA concentration. 
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